Review




Structured Review

Gentex Corporation primary antibodies against the spike s protein
Primary Antibodies Against The Spike S Protein, supplied by Gentex Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+the+spike+s+protein/pmc10410521-284-24-27?v=Gentex+Corporation
Average 90 stars, based on 1 article reviews
primary antibodies against the spike s protein - by Bioz Stars, 2026-08
90/100 stars

Images



Similar Products

90
Gentex Corporation primary antibodies against the spike s protein
Primary Antibodies Against The Spike S Protein, supplied by Gentex Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+the+spike+s+protein/pmc10410521-284-24-27?v=Gentex+Corporation
Average 90 stars, based on 1 article reviews
primary antibodies against the spike s protein - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
GeneTex primary monoclonal antibodies against the spike (s) protein of sars-cov-2 (clone 1a9)
Primary Monoclonal Antibodies Against The Spike (S) Protein Of Sars Cov 2 (Clone 1a9), supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+the+spike+s+protein/pmc08777766-107-19-24?v=GeneTex
Average 90 stars, based on 1 article reviews
primary monoclonal antibodies against the spike (s) protein of sars-cov-2 (clone 1a9) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

96
Sino Biological primary antibody against sars cov s protein
Amino Acid Sequence Alignment of the Full S Protein of <t>SARS-CoV-2</t> Isolates Used in This Study, Related to and Invariant residues are shown as black dots. RBD sequences are shown in gray. Variant mutations are marked in light red.
Primary Antibody Against Sars Cov S Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+the+spike+s+protein/pmc07377714-493-0-6?v=Sino+Biological
Average 96 stars, based on 1 article reviews
primary antibody against sars cov s protein - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

90
Jeno Biotech Inc primary antibody against spike (s) protein
Amino Acid Sequence Alignment of the Full S Protein of <t>SARS-CoV-2</t> Isolates Used in This Study, Related to and Invariant residues are shown as black dots. RBD sequences are shown in gray. Variant mutations are marked in light red.
Primary Antibody Against Spike (S) Protein, supplied by Jeno Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+antibodies+against+the+spike+s+protein/10__1016_slash_j__bmc__2013__04__085-140-32-37?v=Jeno+Biotech+Inc
Average 90 stars, based on 1 article reviews
primary antibody against spike (s) protein - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Amino Acid Sequence Alignment of the Full S Protein of SARS-CoV-2 Isolates Used in This Study, Related to and Invariant residues are shown as black dots. RBD sequences are shown in gray. Variant mutations are marked in light red.

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: Amino Acid Sequence Alignment of the Full S Protein of SARS-CoV-2 Isolates Used in This Study, Related to and Invariant residues are shown as black dots. RBD sequences are shown in gray. Variant mutations are marked in light red.

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: Sequencing, Variant Assay

Design and Encapsulation of mRNA Encoding the SARS-CoV-2 RBD (A) The mRNA construct of ARCoV expressing the SARS-CoV-2 RBD. (B) RBD protein expression from mRNA in HeLa, Huh7, Vero, or HEK293T cells. Cells were transfected with RBD-encoding mRNA (2 μg/mL), and immunoblotting was performed at 48 h after transfection. See also <xref ref-type=Figure S1 . (C) Real-time association and dissociation of the RBD protein with biotin-ACE2. (D) Inhibition of cell entry of the SARS-CoV-2 pseudovirus by the mRNA-encoded RBD protein. Data are shown as mean ± SEM; unpaired t test. ∗∗∗∗ p < 0.0001. (E) Immunofluorescence staining of the mRNA-encoded RBD protein with convalescent sera from three COVID-19 patients. Scale bar, 50 μm. (F) Representative intensity-size graph of ARCoV measured by dynamic light-scattering method. (G) Cryo-TEM image of ARCoV mRNA-LNP. Scale bar, 200 nm. " width="100%" height="100%">

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: Design and Encapsulation of mRNA Encoding the SARS-CoV-2 RBD (A) The mRNA construct of ARCoV expressing the SARS-CoV-2 RBD. (B) RBD protein expression from mRNA in HeLa, Huh7, Vero, or HEK293T cells. Cells were transfected with RBD-encoding mRNA (2 μg/mL), and immunoblotting was performed at 48 h after transfection. See also Figure S1 . (C) Real-time association and dissociation of the RBD protein with biotin-ACE2. (D) Inhibition of cell entry of the SARS-CoV-2 pseudovirus by the mRNA-encoded RBD protein. Data are shown as mean ± SEM; unpaired t test. ∗∗∗∗ p < 0.0001. (E) Immunofluorescence staining of the mRNA-encoded RBD protein with convalescent sera from three COVID-19 patients. Scale bar, 50 μm. (F) Representative intensity-size graph of ARCoV measured by dynamic light-scattering method. (G) Cryo-TEM image of ARCoV mRNA-LNP. Scale bar, 200 nm.

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: Encapsulation, Construct, Expressing, Transfection, Western Blot, Inhibition, Immunofluorescence, Staining

Characterization of Expression of the RDB Encoding mRNA, Related to <xref ref-type=Figure 1 (A) RBD expression in transfected HEK293F cells determined by ELISA. (B) Immunofluorescence analysis of RBD expression (FITC, green) in HeLa cells. HeLa cells were transfected with RBD mRNA (2 μg/ml), and RBD expression was detected with a panel of SARS-CoV-2 specific monoclonal antibodies at 24 hours post transfection. Nuclei was stained using Hhechst (blue). Scale bar: 50 μm. " width="100%" height="100%">

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: Characterization of Expression of the RDB Encoding mRNA, Related to Figure 1 (A) RBD expression in transfected HEK293F cells determined by ELISA. (B) Immunofluorescence analysis of RBD expression (FITC, green) in HeLa cells. HeLa cells were transfected with RBD mRNA (2 μg/ml), and RBD expression was detected with a panel of SARS-CoV-2 specific monoclonal antibodies at 24 hours post transfection. Nuclei was stained using Hhechst (blue). Scale bar: 50 μm.

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: Expressing, Transfection, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Bioprocessing, Staining

Humoral Immune Response in ARCoV-Vaccinated Mice Female BALB/c mice were immunized i.m. with 2 μg (n = 8) or 10 μg (n = 8) of ARCoV or a placebo (n = 5) and boosted with an equivalent dose 14 days later. Serum was collected 7, 14, 21, and 28 days after initial vaccination. (A) Schematic diagram of immunization, sample collection, and challenge schedule. (B) The SARS-CoV-2-specific IgG antibody titer was determined by ELISA. (C and D) NT 50 and PRNT 50 were determined using VSV-based pseudovirus and infectious SARS-CoV-2, respectively. The dashed lines indicate the detection limit of the assay. Data are shown as mean ± SEM. Significance was calculated using a two-way ANOVA with multiple comparisons tests (n.s., not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001). (E) Serum cross-neutralization against SARS-CoV-2 epidemic strains in ARCoV-immunized mice. A plaque reduction neutralization test (PRNT) against the three SARS-CoV-2 epidemic strains was performed using mouse sera collected 28 days after initial immunization. Data were analyzed by one-way ANOVA with multiple comparisons tests. See also <xref ref-type=Figure S5 . " width="100%" height="100%">

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: Humoral Immune Response in ARCoV-Vaccinated Mice Female BALB/c mice were immunized i.m. with 2 μg (n = 8) or 10 μg (n = 8) of ARCoV or a placebo (n = 5) and boosted with an equivalent dose 14 days later. Serum was collected 7, 14, 21, and 28 days after initial vaccination. (A) Schematic diagram of immunization, sample collection, and challenge schedule. (B) The SARS-CoV-2-specific IgG antibody titer was determined by ELISA. (C and D) NT 50 and PRNT 50 were determined using VSV-based pseudovirus and infectious SARS-CoV-2, respectively. The dashed lines indicate the detection limit of the assay. Data are shown as mean ± SEM. Significance was calculated using a two-way ANOVA with multiple comparisons tests (n.s., not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001). (E) Serum cross-neutralization against SARS-CoV-2 epidemic strains in ARCoV-immunized mice. A plaque reduction neutralization test (PRNT) against the three SARS-CoV-2 epidemic strains was performed using mouse sera collected 28 days after initial immunization. Data were analyzed by one-way ANOVA with multiple comparisons tests. See also Figure S5 .

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: Enzyme-linked Immunosorbent Assay, Neutralization, Plaque Reduction Neutralization Test

In Vivo Delivery of ARCoV mRNA-LNP Formulation (A) In vivo BLI of reporter mRNA-LNP in mice. Female BALB/c mice were inoculated with 10 μg of FLuc-encoding reporter mRNA-LNP via different routes and subjected to IVIS Spectrum imaging at the indicated times after administration. (B) Tissue distribution of reporter mRNA-LNP in mice. Empty LNP was employed as a control. (C) Expression of the mRNA-encoded RBD in mice. The serum concentration of the RBD was measured by ELISA 6 h after inoculation. Data are shown as mean ± SEM and analyzed using unpaired t test. ∗∗∗∗ p < 0.0001. (D) Multiplex immunostaining analysis for expression of LNP-delivered mRNA in mouse muscle tissues. Female BALB/c mice (n = 3) were immunized with 10 μg of ARCoV mRNA-LNP, and empty LNP was used as a control (n = 3). Muscle tissue at the injection site was collected 6 h after injection and subjected to multiplex immunofluorescent staining for SARS-CoV-2 RBD (white) as well as other cell markers, including Desmin (gold), CD11b (green), CD163 (red), and CD103 (magenta). Magnifications of the areas boxed in white are shown on the right. Arrows indicate double-positive-stained cells. See also <xref ref-type=Figure S4 . (E) The expression of LNP-delivered mRNA in mouse liver. Liver tissue collected 6 h after injection was stained for the SARS-CoV-2 RBD (white) and multiple cell markers for glutamine synthetase (green), CD31 (magenta), CD163 (cyan), and Arg1 (red). Magnifications of the areas boxed in white are shown on the right. Arrows indicate the double-positive-stained cells. CV, central vein. " width="100%" height="100%">

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: In Vivo Delivery of ARCoV mRNA-LNP Formulation (A) In vivo BLI of reporter mRNA-LNP in mice. Female BALB/c mice were inoculated with 10 μg of FLuc-encoding reporter mRNA-LNP via different routes and subjected to IVIS Spectrum imaging at the indicated times after administration. (B) Tissue distribution of reporter mRNA-LNP in mice. Empty LNP was employed as a control. (C) Expression of the mRNA-encoded RBD in mice. The serum concentration of the RBD was measured by ELISA 6 h after inoculation. Data are shown as mean ± SEM and analyzed using unpaired t test. ∗∗∗∗ p < 0.0001. (D) Multiplex immunostaining analysis for expression of LNP-delivered mRNA in mouse muscle tissues. Female BALB/c mice (n = 3) were immunized with 10 μg of ARCoV mRNA-LNP, and empty LNP was used as a control (n = 3). Muscle tissue at the injection site was collected 6 h after injection and subjected to multiplex immunofluorescent staining for SARS-CoV-2 RBD (white) as well as other cell markers, including Desmin (gold), CD11b (green), CD163 (red), and CD103 (magenta). Magnifications of the areas boxed in white are shown on the right. Arrows indicate double-positive-stained cells. See also Figure S4 . (E) The expression of LNP-delivered mRNA in mouse liver. Liver tissue collected 6 h after injection was stained for the SARS-CoV-2 RBD (white) and multiple cell markers for glutamine synthetase (green), CD31 (magenta), CD163 (cyan), and Arg1 (red). Magnifications of the areas boxed in white are shown on the right. Arrows indicate the double-positive-stained cells. CV, central vein.

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: In Vivo, Formulation, Imaging, Control, Expressing, Concentration Assay, Enzyme-linked Immunosorbent Assay, Multiplex Assay, Immunostaining, Injection, Staining

SARS-CoV-2 RBD Expression Profile in Muscle Tissue of ARCoV-Immunized Mice, Related to <xref ref-type=Figure 2 Intramuscular injection of ARCoV induced local RBD expression in intramuscular lymph nodes. Multiplex immunofluorescent staining of intramuscular injection sites showed SARS-CoV-2 RBD and CD11b-positive monocytes expression in the intramuscular lymph nodes of the ARCoV mRNA-LNP -inoculated mice. Scale bar: 500 μm. Magnifications of the areas boxed in white are shown on the right. Colored arrows indicate the double-stained cells that are magnified beside. Scale bar: 200 μm. " width="100%" height="100%">

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: SARS-CoV-2 RBD Expression Profile in Muscle Tissue of ARCoV-Immunized Mice, Related to Figure 2 Intramuscular injection of ARCoV induced local RBD expression in intramuscular lymph nodes. Multiplex immunofluorescent staining of intramuscular injection sites showed SARS-CoV-2 RBD and CD11b-positive monocytes expression in the intramuscular lymph nodes of the ARCoV mRNA-LNP -inoculated mice. Scale bar: 500 μm. Magnifications of the areas boxed in white are shown on the right. Colored arrows indicate the double-stained cells that are magnified beside. Scale bar: 200 μm.

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: Expressing, Injection, Multiplex Assay, Staining

Immunogenicity and Protection of a Single Dose of ARCoV in Mice, Related to <xref ref-type=Figure 3 BALB/c mice were intramuscularly immunized with 2 μg (n = 7) or 30 μg (n = 8) of the ARCoV vaccine or Placebo (n = 5). Serum was collected at 14, 28 days post immunization and analyzed by ELISA (A) and pseudovirus neutralization assay (B). Data are shown as mean ± SEM. Significance was calculated using a two-way ANOVA with multiple comparison tests (n.s., not significant; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001). Six to eight weeks after immunization, all immunized mice were inoculated intranasally with the SARS-CoV-2 mouse-adapted strain MASCp6, and their lungs (C) and trachea (D) were collected for detection of viral RNA loads at 5 days post challenge. Data are shown as mean ± SEM; Significance was calculated using a one-way ANOVA with multiple comparison tests. ( ∗∗ p < 0.01; ∗∗∗∗ p < 0.0001). " width="100%" height="100%">

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: Immunogenicity and Protection of a Single Dose of ARCoV in Mice, Related to Figure 3 BALB/c mice were intramuscularly immunized with 2 μg (n = 7) or 30 μg (n = 8) of the ARCoV vaccine or Placebo (n = 5). Serum was collected at 14, 28 days post immunization and analyzed by ELISA (A) and pseudovirus neutralization assay (B). Data are shown as mean ± SEM. Significance was calculated using a two-way ANOVA with multiple comparison tests (n.s., not significant; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001). Six to eight weeks after immunization, all immunized mice were inoculated intranasally with the SARS-CoV-2 mouse-adapted strain MASCp6, and their lungs (C) and trachea (D) were collected for detection of viral RNA loads at 5 days post challenge. Data are shown as mean ± SEM; Significance was calculated using a one-way ANOVA with multiple comparison tests. ( ∗∗ p < 0.01; ∗∗∗∗ p < 0.0001).

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: Immunopeptidomics, Enzyme-linked Immunosorbent Assay, Neutralization, Comparison

SARS-CoV-2-Specific T Cell Immune Response in ARCoV-Vaccinated Mice (A) SARS-CoV-2 RBD-specific CD4 + and CD8 + Tem cells (CD44 + CD62L − ) in splenocytes were detected by flow cytometry. (B and C) ELISPOT assay for IFN-γ, TNF-α, IL-2, IL-4, and IL-6 in splenocytes. Data are shown as mean ± SEM. Significance was calculated using unpaired t test (n.s., not significant, ∗ p < 0.05, ∗∗ p < 0.01).

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: SARS-CoV-2-Specific T Cell Immune Response in ARCoV-Vaccinated Mice (A) SARS-CoV-2 RBD-specific CD4 + and CD8 + Tem cells (CD44 + CD62L − ) in splenocytes were detected by flow cytometry. (B and C) ELISPOT assay for IFN-γ, TNF-α, IL-2, IL-4, and IL-6 in splenocytes. Data are shown as mean ± SEM. Significance was calculated using unpaired t test (n.s., not significant, ∗ p < 0.05, ∗∗ p < 0.01).

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: Flow Cytometry, Enzyme-linked Immunospot

Serum Neutralization Comparison between SARS-CoV-2 Clinical Isolate and the Mouse-Adapted Strain MASCp6, Related to <xref ref-type=Figure 5 Standard PRNT assay were performed with sera from ARCoV immunized mice (n = 15) using SARS-CoV-2 strains 131 and MASCp6, respectively. Data are analyzed by paired t test. (n.s., not significant). " width="100%" height="100%">

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: Serum Neutralization Comparison between SARS-CoV-2 Clinical Isolate and the Mouse-Adapted Strain MASCp6, Related to Figure 5 Standard PRNT assay were performed with sera from ARCoV immunized mice (n = 15) using SARS-CoV-2 strains 131 and MASCp6, respectively. Data are analyzed by paired t test. (n.s., not significant).

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: Neutralization, Comparison, Plaque Reduction Neutralization Test

Protection of ARCoV against SARS-CoV-2 Challenge in Mice Forty days after the initial immunization, mice were inoculated i.n. with the mouse-adapted SARS-CoV-2 (MASCp6), and the indicated tissues were collected 5 days after challenge for detection of viral loads and lung pathology. (A and B) Viral RNA loads in the lungs and trachea were determined by qRT-PCR. Data are shown as mean ± SEM ( ∗∗∗∗ p < 0.0001). (C) Immunostaining of lung tissues with a SARS-CoV-2 S-specific mAb. Scale bar, 100 μm. (D) ISH assay for SARS-CoV-2 RNA. Scale bar, 50 μm. Positive signals are shown in brown. (E) H&E staining of lung pathology. Scale bar, 100 μm. Representative images from 4 or 5 mice are shown. See also <xref ref-type=Figure S5 . " width="100%" height="100%">

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: Protection of ARCoV against SARS-CoV-2 Challenge in Mice Forty days after the initial immunization, mice were inoculated i.n. with the mouse-adapted SARS-CoV-2 (MASCp6), and the indicated tissues were collected 5 days after challenge for detection of viral loads and lung pathology. (A and B) Viral RNA loads in the lungs and trachea were determined by qRT-PCR. Data are shown as mean ± SEM ( ∗∗∗∗ p < 0.0001). (C) Immunostaining of lung tissues with a SARS-CoV-2 S-specific mAb. Scale bar, 100 μm. (D) ISH assay for SARS-CoV-2 RNA. Scale bar, 50 μm. Positive signals are shown in brown. (E) H&E staining of lung pathology. Scale bar, 100 μm. Representative images from 4 or 5 mice are shown. See also Figure S5 .

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: Quantitative RT-PCR, Immunostaining, In Situ Hybridization, Staining

Immune Correlate of Protection against SARS-CoV-2 in ARCoV-Vaccinated Mice (A and B) Paired sera were collected from animals receiving two doses (2 or 10 μg) or a single dose (2 or 30 μg) of vaccination before (Pre) and 5 days after (Post) SARS-CoV-2 challenge. The NT 50 values were analyzed for differences using a paired t test (n.s., not significant, ∗ p < 0.05, ∗∗ p < 0.01). (C and D) Correlations of viral loads and protective efficacy by PRNT 50 and NT 50 . Animals receiving a placebo (n = 10) and ARCoV (n = 31) vaccination were included in this analysis. The p values and R 2 values reflect Spearman rank-correlation tests. See also <xref ref-type=Figure S5 . " width="100%" height="100%">

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: Immune Correlate of Protection against SARS-CoV-2 in ARCoV-Vaccinated Mice (A and B) Paired sera were collected from animals receiving two doses (2 or 10 μg) or a single dose (2 or 30 μg) of vaccination before (Pre) and 5 days after (Post) SARS-CoV-2 challenge. The NT 50 values were analyzed for differences using a paired t test (n.s., not significant, ∗ p < 0.05, ∗∗ p < 0.01). (C and D) Correlations of viral loads and protective efficacy by PRNT 50 and NT 50 . Animals receiving a placebo (n = 10) and ARCoV (n = 31) vaccination were included in this analysis. The p values and R 2 values reflect Spearman rank-correlation tests. See also Figure S5 .

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques:

Immunogenicity of ARCoV in Cynomolgus Macaques Three- to six-year-old male or female cynomolgus macaques were immunized i.m. with 100 μg (n = 10) or 1,000 μg (n = 10) of ARCoV and boosted with the same dose at a 14-day interval. Serum was collected on days 0, 14, and 28 after initial immunization and subjected to antibody assays. (A) Schematic diagram of ARCoV immunization, sample collection, and immunological assays. (B and C) The IgG titers and NT 50 values were determined by ELISA and SARS-CoV-2 pseudovirus neutralization assay, respectively. Dotted lines indicate the limits of detection. Data are shown as mean ± SEM. Significance was calculated using two-way ANOVA with multiple comparisons tests (n.s., not significant, ∗ p < 0.05, ∗∗∗∗ p < 0.0001). (D and E) Production of IFN-γ or IL-4 in PBMCs stimulated by the SARS-CoV-2 RBD was measured by ELISPOT assay or flow cytometry. Data are shown as mean ± SEM. Significance was calculated using one-way ANOVA with multiple comparisons tests (n.s., not significant, ∗∗∗∗ , p < 0.0001). See also .

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet: Immunogenicity of ARCoV in Cynomolgus Macaques Three- to six-year-old male or female cynomolgus macaques were immunized i.m. with 100 μg (n = 10) or 1,000 μg (n = 10) of ARCoV and boosted with the same dose at a 14-day interval. Serum was collected on days 0, 14, and 28 after initial immunization and subjected to antibody assays. (A) Schematic diagram of ARCoV immunization, sample collection, and immunological assays. (B and C) The IgG titers and NT 50 values were determined by ELISA and SARS-CoV-2 pseudovirus neutralization assay, respectively. Dotted lines indicate the limits of detection. Data are shown as mean ± SEM. Significance was calculated using two-way ANOVA with multiple comparisons tests (n.s., not significant, ∗ p < 0.05, ∗∗∗∗ p < 0.0001). (D and E) Production of IFN-γ or IL-4 in PBMCs stimulated by the SARS-CoV-2 RBD was measured by ELISPOT assay or flow cytometry. Data are shown as mean ± SEM. Significance was calculated using one-way ANOVA with multiple comparisons tests (n.s., not significant, ∗∗∗∗ , p < 0.0001). See also .

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: Immunopeptidomics, Enzyme-linked Immunosorbent Assay, Neutralization, Enzyme-linked Immunospot, Flow Cytometry

Journal: Cell

Article Title: A Thermostable mRNA Vaccine against COVID-19

doi: 10.1016/j.cell.2020.07.024

Figure Lengend Snippet:

Article Snippet: Primary antibody against SARS-CoV S protein (Sino Biological) was incubated for 2 hours in a humidified chamber at 37°C, followed by detection using the TSA-dendronfluorophores.

Techniques: Virus, Recombinant, Transfection, Enzyme-linked Immunospot, Enzyme-linked Immunosorbent Assay, Luciferase, RNAscope, Software